Fun with Funds: Exploring the MSCI World Pharmaceuticals, Biotechnology, and Life Sciences Index
The MSCI World Pharmaceuticals, Biotechnology, and Life Sciences Index (USD) is a key benchmark for the biotech and pharmaceutical industry.
The Art of Not Killing a Project: Navigating the Fine Line Between Risk and Reward
Killing a project is easy. There’s a laundry list of reasons why something “shouldn’t move forward”: it’s
Ex-Factor: Why Everyone Loves to Advertise Their Exes (and Why It’s Mostly Nonsense)
LinkedIn profiles boasting titles like ex-McKinsey, ex-Bain, ex-Novartis, or ex-Roche. It’s as if these professionals are collecting exes, not in their personal lives (well, hopefully), but in their résumés, brandishing them like badges of honor.
Reviving EU Pharma: Draghi’s Blueprint for Survival
In European boardrooms, where modesty often masquerades as pragmatism, it is rare for a leader to sound the alarm with
The problem with POS
The Problem with Probability of Success (POS) in Biotech and Pharma
Probability of Success (POS) is a widely used metric
Progression-Free Survival: The Metric That Divides Science, Business, and Payors
Few metrics in modern oncology trials command the prominence of progression-free survival (PFS). As a measure of time until disease
Europe’s Competitiveness Compass: Will Pension Funds Finally Back Innovation?
Brussels has a new plan. The Competitiveness Compass, the European Commission’s latest attempt to reinvigorate the EU economy, comes
Licensing Deals: David’s Slingshot, Goliath’s Throne
For decades, licensing deals have been the biotech-pharma relationship’s bread and butter—a veritable match made in heaven, or
Europe’s Biotech Grants: A Lifeline or a Leash?
Europe’s biotech sector has always been fond of government grants. Programs like Horizon Europe, with its eye-watering €95.5
To Quad or Not to Squad?
Have you noticed something peculiar creeping into the corporate world? A proliferation of titles that sound less like professional roles
